Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports


The Human Parainfluenza Viruses Diagnostics Market is likely to scintillate going forward. With various cloud options to explore, the healthcare industry is expected to be at a newer high in the forecast period. In other words, organizations across the globe are advancing their downtime regarding digital business initiatives. They are swiftly moving towards the cloud for modernizing the environments, enhancing system reliability, supporting hybrid work models, and addressing the other new-fangled realities surfacing in recent times. This would be the outlook of the healthcare vertical in the upcoming period.

Increasing burden of infectious diseases on healthcare system is a main concern across the globe and developing countries have heavy share of infectious disease burden. Human parainfluenza virus infection is becoming of major concern among children as it can cause life threatening lower respiratory tract infection.

Human parainfluenza virus (HPIV) generally cause respiratory illness in infants and children below 5 years and is the second most common cause of hospitalization in children below 5 years of age. Human parainfluenza viruses are group of four single stranded RNA viruses called HPIV 1-4, with HPIV-1 and HPIV-3 being the most virulent.

The virus causes damage to lining of small airways in respiratory tract. There are number of tests available in laboratory for detection of HPIV virus in respiratory sample of patients. The most commonly used method is cell culture using serological and nasal swab specimens. Chest x-ray is used to detect the progression of disease in young children.

Get Sample Copy of this Report@

Improvement in virus culture techniques using immunofluorescence techniques have reduced the time to results. Some of the commercially available human parainfluenza virus diagnostic testing assay kits are R-DiaHPIV, RT-PCR, RespiFast RG Panel, FTD HPIV, Techne PrimePRO QPCR RNA kits, SimulFluor, RealStar PIV RT-PCR Kit etc.

Human parainfluenza has been listed under priority infectious disease with epidemic potential. The program is established for surveillance and monitoring of pathogens with high epidemic potential in resource limited settings and capacities for fast ramp up of diagnostic testing in central lab settings of epicentres of an outbreak and at the point of need. Under this program Alere Inc. has developed RT-PCR assay kit for diagnosis of human parainfluenza virus, which obtained CE mark approval in 2015.

Growing incidence of infectious diseases and repeated outbreaks of parainfluenza virus in developing countries such as China, Middle East region etc. are the prime factors driving the growth of global human parainfluenza virus diagnostics market. Besides this, improvements in cell culture techniques, and development of advanced molecular testing methods for detection of parainfluenza virus in human specimen is expected to push the market over the forecast period.

However, difficulty in isolation of virus, lack of routine surveillance for some of the HPIV species are the factors restraining the growth of global human parainfluenza virus diagnostics market. Unavailability of point-of-care testing methods for human parainfluenza virus diagnosis poses significant obstacle in deciding treatment options.

Request for Table of Content@

The global market for human parainfluenza testing is segmented on basis of test type, end user and geography.

 Test Type
End User
  • Hospitals
  • Diagnostic
  • Laboratories

Among all test types, PCR assays are the most commonly used HPIV diagnostics. Molecular testing assays such as reverse transcriptase polymerase chain reaction are the most recent technique for diagnosis of human parainfluenza viruses. RT-PCR based methods are the most sensitive methods to detect HPIV and thus are recommended as confirmatory tests for HPIV type.

On the basis of geography, global parainfluenza virus diagnostic testing market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is projected to hold largest shares in the global market primarily due to growing incidence of parainfluenza virus and innovations in diagnostic techniques. Asia pacific human parainfluenza virus diagnostics testing market is anticipated to witness prominent growth during the forecast period owing to increased healthcare expenditure and repeated outbreaks of infectious diseases in developing countries such as India and China.

Some of the key players present in global human parainfluenza virus testing market are Quidel Corporation, Diagenode Diagnostics, QIAGEN N.V., Fast-track diagnostics Ltd., Thermo Fisher Scientific Inc., Sigma-Aldrich Co. LLC (Merck KGaA), Liferiver Bio-Tech (United States) Corp., Altona Diagnostics, Alere Inc. etc. among others.

Access Full Report@

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales –
Website –

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts